Clinical studies have shown that the subcutaneous administration of a monoclonal antibody to PCSK9 reduced LDL levels in a dose-dependent manner in up to 61% in patients with familial or nonfamilial hypercholesterolemia [28]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.